Chapter 7: Hypertension — Clinical and Pharmacological Series — Module: HTN-01 — Definition, Classification, and Pathophysiology Tier: Tier 2
1. A 64-year-old man with hypertension, stage 3b CKD (eGFR 38 mL/min/1.73m²), and urine albumin-to-creatinine ratio (ACR) of 580 mg/g is on lisinopril 20 mg daily and amlodipine 10 mg daily. His BP is 142/88 mmHg and serum potassium is 5.1 mEq/L. His cardiologist wants to add spironolactone for further BP control and renal protection. Which of the following most accurately describes the risk profile of this addition?
A) Spironolactone is the ideal third agent because mineralocorticoid receptor blockade provides additive renal protection beyond ACE inhibition alone, and the combination is safe at any level of CKD when potassium is below 5.5 mEq/L
B) Adding spironolactone to an ACE inhibitor in a patient with eGFR 38 and baseline potassium of 5.1 mEq/L carries significant risk of life-threatening hyperkalemia; both agents suppress aldosterone-mediated potassium excretion through complementary mechanisms, and CKD further impairs the renal capacity to excrete potassium — making this combination high-risk without very close monitoring or potassium-binding resin support
C) Spironolactone is absolutely contraindicated in all patients with eGFR below 45 mL/min/1.73m² regardless of potassium level, and this recommendation should be declined based on an absolute eGFR threshold
D) The combination of ACE inhibitor and spironolactone is safe in CKD because both agents lower systemic vascular resistance rather than affecting potassium homeostasis, and the renal protective benefit outweighs any electrolyte concern
E) Amlodipine should be discontinued before spironolactone is added because the combination of a CCB and a mineralocorticoid receptor antagonist causes additive efferent arteriole vasodilation precipitating AKI in CKD patients
ANSWER: B
Rationale:
This question asked you to evaluate the risk of combining an ACE inhibitor with spironolactone in a patient with CKD and borderline hyperkalemia. Option B is correct: this combination carries real and serious hyperkalemia risk in this specific patient. ACE inhibitors suppress aldosterone through RAAS blockade, reducing renal potassium excretion. Spironolactone directly blocks the mineralocorticoid receptor in the collecting duct, further impairing the primary mechanism of renal potassium elimination. In a patient with eGFR 38 — already significantly reduced renal potassium excretion capacity — and a baseline potassium of 5.1 mEq/L, adding a second agent that suppresses potassium excretion through a complementary mechanism creates high risk for clinically dangerous hyperkalemia. This combination can be used in CKD with careful monitoring, potassium dietary restriction, and potentially a potassium binder (patiromer or sodium zirconium cyclosilicate), but must not be added casually.
Option A: Option A is incorrect — the combination is not safe below 5.5 mEq/L in CKD; the 5.1 mEq/L baseline here warrants caution, not reassurance.
Option C: Option C is incorrect — there is no absolute eGFR threshold of 45 mL/min/1.73m² constituting a hard contraindication; the decision is risk-benefit with close monitoring.
Option D: Option D is incorrect — both ACE inhibitors and spironolactone profoundly affect potassium homeostasis; the characterization that they only lower systemic vascular resistance is pharmacologically wrong.
Option E: Option E is incorrect — CCBs do not cause efferent arteriole vasodilation; that is a property of RAAS inhibitors; amlodipine discontinuation is not indicated here.
2. A 58-year-old Black man with hypertension and no other significant comorbidities has BP of 158/96 mmHg on hydrochlorothiazide 25 mg daily. His physician is considering adding a second agent. Multiple clinical trials including ALLHAT (a landmark trial comparing antihypertensive drug classes — thiazide, CCB, and ACE inhibitor — in high-risk patients) have demonstrated that Black patients with hypertension have attenuated BP response to ACE inhibitor monotherapy compared to thiazide or CCB monotherapy. Which of the following most accurately explains the pharmacological basis for this observation and identifies the most appropriate second agent?
A) Black patients have genetically higher ACE enzyme activity preventing adequate Ang II suppression at standard doses; doubling the ACE inhibitor dose before adding a second class is the correct first step
B) The attenuated response to ACE inhibitor monotherapy in Black patients reflects a higher prevalence of low-renin hypertension — when renin is already suppressed, further RAAS blockade produces less BP reduction; a dihydropyridine CCB such as amlodipine is the most appropriate addition, as volume-dependent and renin-independent mechanisms are better addressed by CCBs and thiazides; this difference largely disappears with combination therapy
C) Black patients have a pharmacogenomic variant in the bradykinin receptor that reduces ACE inhibitor efficacy by preventing bradykinin accumulation; ARBs should replace the thiazide as the second agent because they do not depend on bradykinin for their effect
D) The difference reflects differential drug metabolism — higher CYP3A4 activity in Black patients accelerates ACE inhibitor clearance; pharmacokinetic dose adjustment eliminates the disparity
E) The attenuated response to ACE inhibitors in Black patients is an artifact of older trials disproven by recent outcome data; ACE inhibitors are equally effective across all racial groups and should be added without hesitation
ANSWER: B
Rationale:
This question asked you to identify the pharmacological basis for the differential BP response to ACE inhibitor monotherapy in Black patients and determine the appropriate next agent. Option B is correct: the mechanistic explanation most consistently supported by evidence is the higher prevalence of low-renin hypertension in Black patients. When the RAAS is already relatively suppressed — as it tends to be in volume-dependent, low-renin hypertension — ACE inhibitors produce less incremental Ang II suppression and therefore less BP reduction as monotherapy. Thiazide diuretics and dihydropyridine CCBs are effective regardless of renin status because they lower BP through volume reduction and direct vasodilation respectively. Importantly, when ACE inhibitors are combined with a thiazide or CCB, the differential response largely disappears — confirming that the limitation is monotherapy mechanism mismatch, not a universal ACE inhibitor resistance. Amlodipine is an appropriate second agent.
Option A: Option A is incorrect — the differential is not explained by higher ACE enzyme activity, and dose escalation alone is not the standard approach.
Option C: Option C is incorrect — the bradykinin receptor variant explanation is not the established mechanistic basis, and replacing the thiazide with an ARB is not the standard recommendation.
Option D: Option D is incorrect — the differential is not pharmacokinetically explained by CYP3A4 differences.
Option E: Option E is incorrect — the observation is well-replicated and clinically recognized; dismissing it as artifact is not consistent with current evidence or guidelines.
3. A 71-year-old woman with isolated systolic hypertension (ISH), HFpEF (EF 58%), bilateral knee osteoarthritis, and BP of 168/72 mmHg on furosemide 40 mg daily for volume management presents for antihypertensive intensification. Which of the following best describes the most important initial pharmacological step?
A) Add a beta-blocker immediately because beta-blockers are the cornerstone of heart failure pharmacotherapy and their use is mandated in any patient with HFpEF regardless of BP or heart rate
B) Add an ACE inhibitor or ARB as the preferred antihypertensive because RAAS blockade reduces LV filling pressures through efferent vasodilation, directly improving diastolic compliance and the underlying HFpEF pathophysiology
C) Discontinue the NSAIDs she is taking for osteoarthritis pain before adding a new antihypertensive — NSAID-mediated sodium retention and prostaglandin inhibition contribute directly to both her hypertension and HFpEF decompensation, and addressing this reversible contributor may reduce the need for additional pharmacotherapy
D) Add amlodipine because dihydropyridine CCBs are the preferred agent in ISH and HFpEF given their vascular selectivity and absence of negative inotropic effect
E) Add hydralazine plus nitrate because direct arterial and venous vasodilation reduces both afterload and preload in HFpEF without affecting neurohormonal activation
ANSWER: C
Rationale:
This question asked you to identify competing pharmacological priorities in a patient with ISH, HFpEF, osteoarthritis, and volume management on furosemide. Option C is correct and represents the most important initial step: NSAIDs inhibit cyclooxygenase (COX)-mediated prostaglandin synthesis in the kidney, reducing prostaglandin E2-mediated afferent arteriole vasodilation and promoting sodium and water retention. In a patient with HFpEF already requiring a loop diuretic for volume management, NSAID use directly counteracts the furosemide and worsens both hypertension and volume status. Discontinuing NSAIDs — substituting acetaminophen or topical diclofenac for osteoarthritis pain — is the most pharmacologically rational first step before adding another antihypertensive. Option B is partially correct in that RAAS blockade is a reasonable antihypertensive choice in HFpEF, but is not the most important immediate step when a reversible contributor (NSAID use) is present and unaddressed. Option D is correct that amlodipine is safe in HFpEF — dihydropyridine CCBs do not cause significant negative inotropy — but again, removing NSAIDs takes priority over adding agents.
Option A: Option A is incorrect — beta-blockers are indicated in HFrEF for mortality benefit; their role in HFpEF is not established and they are not mandated in this setting.
Option E: Option E is incorrect — hydralazine-nitrate is a specific alternative in HFrEF patients who cannot tolerate RAAS inhibitors; it is not a preferred regimen for ISH in HFpEF.
4. A 47-year-old man with hypertension, type 2 diabetes, and microalbuminuria is well controlled on lisinopril 10 mg daily (BP 128/78 mmHg, potassium 4.2 mEq/L, eGFR 72). His endocrinologist adds canagliflozin. Three months later his BP is 122/74 mmHg and urine ACR has fallen from 95 to 42 mg/g. Which of the following best explains the BP and albuminuria reduction from the SGLT-2 (sodium-glucose cotransporter-2) inhibitor beyond its glycemic effect?
A) Canagliflozin reduces BP through direct proximal tubular RAAS inhibition, producing additive Ang II suppression on top of the lisinopril effect
B) SGLT-2 inhibitors cause osmotic diuresis and natriuresis by blocking proximal tubular glucose-sodium co-transport, reducing intravascular volume and BP; simultaneously, increased sodium delivery to the macula densa from reduced proximal reabsorption activates tubuloglomerular feedback, constricting the afferent arteriole and reducing intraglomerular pressure — a mechanism that is complementary to and additive with RAAS blockade
C) Canagliflozin reduces albuminuria solely through glycemic improvement — lower blood glucose reduces non-enzymatic glycosylation of the glomerular basement membrane, restoring filtration barrier integrity independently of any hemodynamic mechanism
D) SGLT-2 inhibitors reduce BP by blocking L-type calcium channels in vascular smooth muscle through an off-target pharmacological effect demonstrated in recent mechanistic studies
E) The BP and albuminuria reduction reflects weight loss from glucosuria — caloric loss through urinary glucose excretion reduces adipose tissue mass, lowering leptin-driven sympathetic nervous system (SNS) activation and reducing BP through a purely indirect mechanism
ANSWER: B
Rationale:
This question asked you to identify the mechanistic basis for the cardiorenal benefits of SGLT-2 inhibitors beyond glycemic control. Option B is correct: SGLT-2 inhibitors block glucose and sodium co-transport in the proximal tubule, producing osmotic diuresis and natriuresis — reducing intravascular volume and lowering BP independent of insulin or glucose-mediated pathways. The glomerular mechanism is particularly important: blocking proximal tubular sodium reabsorption increases sodium delivery to the macula densa, activating tubuloglomerular feedback and causing afferent arteriole constriction, which reduces intraglomerular hydraulic pressure. This mechanism is complementary to RAAS blockade — RAAS inhibition reduces efferent tone, SGLT-2 inhibition increases macula densa sodium and constricts the afferent — providing additive intraglomerular pressure reduction. This dual mechanism underlies the cardiovascular and renal outcome benefits demonstrated in CREDENCE (canagliflozin in patients with type 2 diabetes and CKD), DAPA-CKD (dapagliflozin in CKD), and EMPA-KIDNEY (empagliflozin in CKD).
Option A: Option A is incorrect — SGLT-2 inhibitors do not directly inhibit the RAAS; any renin modulation is indirect through volume changes.
Option C: Option C is incorrect — albuminuria reduction with SGLT-2 inhibitors occurs rapidly, before meaningful glycemic restoration of glomerular integrity, confirming a hemodynamic mechanism.
Option D: Option D is incorrect — SGLT-2 inhibitors do not block L-type calcium channels; this is fabricated.
Option E: Option E is incorrect — renal and BP effects occur independently of weight change and too rapidly to be explained by adipose tissue reduction.
5. A 55-year-old man started on lisinopril develops a persistent dry cough 3 weeks after initiation. He has no wheezing or dyspnea. Which of the following most accurately describes the mechanism and appropriate management?
A) The dry cough is caused by ACE inhibitor-induced accumulation of bradykinin in the airways — ACE normally degrades bradykinin, and its inhibition leads to bradykinin excess stimulating airway C-fiber afferents; switching to an ARB resolves the cough in the vast majority of patients because ARBs do not inhibit ACE and bradykinin continues to be degraded normally
B) The dry cough reflects ACE inhibitor-induced bronchospasm through inhibition of prostaglandin synthesis in airway epithelium; switching to an ARB will not resolve it because ARBs share this prostaglandin-mediated mechanism
C) The dry cough is a class effect shared equally by ACE inhibitors and ARBs because both elevate bradykinin through complementary mechanisms; the only solution is switching to a CCB or thiazide
D) The dry cough reflects ACE inhibitor-induced gastroesophageal reflux through lower esophageal sphincter relaxation mediated by nitric oxide accumulation; PPI therapy resolves the cough without requiring drug discontinuation
E) The dry cough is caused by ACE inhibitor-induced accumulation of substance P only; switching to an ARB will not resolve it because substance P accumulation is AT1 (angiotensin type 1) receptor-receptor independent
ANSWER: A
Rationale:
This question asked you to identify the mechanism of ACE inhibitor cough and the appropriate drug switch. Option A is correct: ACE degrades not only angiotensin I but also bradykinin, a potent vasodilator and pro-inflammatory peptide. When ACE is inhibited, bradykinin accumulates in tissues including the airways. Bradykinin stimulates bradykinin B2 receptors on airway C-fiber sensory afferents, triggering a reflex cough — a class effect of all ACE inhibitors, occurring in approximately 10–15% of patients and at higher rates in Asian populations. ARBs block the AT1 receptor without affecting ACE activity — bradykinin continues to be degraded normally, and the cough resolves. Switching from an ACE inhibitor to an ARB is the standard management for ACE inhibitor cough, and ARBs provide equivalent or superior antihypertensive and renal protective effects.
Option B: Option B is incorrect — the cough is bradykinin-mediated, not prostaglandin-mediated, and ARBs do resolve it.
Option C: Option C is incorrect — ARBs do not cause the same cough; this is one of the clinically important distinctions between the two drug classes.
Option D: Option D is incorrect — ACE inhibitor cough is not caused by esophageal reflux and does not respond to PPI therapy.
Option E: Option E is incorrect — while substance P (also degraded by ACE) may contribute, the primary mediator is bradykinin; and ARBs do resolve the cough in the vast majority of patients.
6. A 52-year-old woman with hypertension and recurrent calcium oxalate kidney stones presents for antihypertensive selection. eGFR is 78, BP is 148/92 mmHg on no medications. Which antihypertensive drug class reduces urinary calcium excretion and potentially reduces her risk of recurrent nephrolithiasis?
A) ACE inhibitors, because RAAS blockade reduces glomerular filtration pressure and decreases the filtered calcium load reaching the tubule
B) Loop diuretics such as furosemide, because blockade of the Na-K-2Cl transporter in the thick ascending limb reduces calcium reabsorption and lowers urinary calcium excretion
C) Beta-blockers, because reduction in renin secretion lowers aldosterone, which decreases calcium excretion through mineralocorticoid receptor-mediated collecting duct mechanisms
D) ARBs, because AT1 receptor blockade in the proximal tubule directly stimulates calcium-ATPase activity and increases tubular calcium reabsorption
E) Thiazide diuretics, because blockade of the Na-Cl cotransporter in the distal convoluted tubule reduces intracellular sodium in tubular epithelial cells, stimulating the basolateral Na-Ca exchanger to increase calcium reabsorption from tubular fluid — producing hypocalciuria that reduces urinary calcium available for stone formation
ANSWER: E
Rationale:
This question asked you to identify the antihypertensive drug class that reduces urinary calcium excretion and benefits patients with calcium nephrolithiasis. Option E is correct: thiazide diuretics produce hypocalciuria through a well-established tubular mechanism. By blocking the Na-Cl cotransporter (NCC) in the distal convoluted tubule, thiazides reduce intracellular sodium in the tubular epithelial cell, stimulating the basolateral Na-Ca exchanger (NCX1) to extrude sodium in exchange for calcium uptake — increasing calcium reabsorption from tubular fluid. The resulting hypocalciuria reduces urinary calcium concentration available to form calcium oxalate or calcium phosphate crystals, and thiazides are established pharmacological therapy for hypercalciuric nephrolithiasis. Option B is critically incorrect: loop diuretics increase urinary calcium excretion (calciuresis) by blocking calcium reabsorption in the thick ascending limb — they worsen hypercalciuric nephrolithiasis and are not indicated here.
Option A: Option A is incorrect — ACE inhibitors do not directly reduce urinary calcium excretion through the mechanism described.
Option C: Option C is incorrect — beta-blockers do not meaningfully reduce urinary calcium excretion through aldosterone-mediated collecting duct mechanisms.
Option D: Option D is incorrect — ARBs do not directly stimulate calcium-ATPase through AT1 receptor blockade in the proximal tubule; this mechanism is fabricated.
7. A 61-year-old man with hypertension and gout (serum uric acid 9.2 mg/dL, on allopurinol) is being evaluated for antihypertensive therapy. Which of the following antihypertensive agents has a property directly beneficial for his gout through a specific uricosuric mechanism, and what is that mechanism?
A) Amlodipine, because dihydropyridine CCBs inhibit xanthine oxidase in vascular smooth muscle, reducing local uric acid production and lowering serum urate
B) Hydrochlorothiazide, because thiazide diuretics increase renal uric acid excretion by competing with urate at the proximal tubular secretion transporter, producing a uricosuric effect
C) Losartan, because in addition to its AT1 receptor blocking effect, losartan inhibits the URAT1 (the proximal tubular urate reabsorption transporter) urate reabsorption transporter in the proximal tubule through an AT1-independent mechanism, producing a clinically meaningful uricosuric effect that lowers serum uric acid by approximately 20–25% — a property unique to losartan among ARBs
D) Lisinopril, because ACE inhibitor-mediated reduction in angiotensin II lowers xanthine oxidase activity in renal tubular cells, reducing intrarenal uric acid production
E) Metoprolol, because beta-1 selective blockade reduces renal sympathetic tone, increasing renal blood flow and enhancing urinary uric acid clearance through flow-dependent tubular excretion
ANSWER: C
Rationale:
This question asked you to identify the antihypertensive agent with a clinically relevant uricosuric property beneficial in gout. Option C is correct: losartan is unique among ARBs in possessing a uricosuric effect independent of its AT1 receptor blockade. Losartan and its active metabolite EXP3174 (the pharmacologically active form of losartan) inhibit the URAT1 (SLC22A12) urate reabsorption transporter in the proximal tubule, reducing tubular uric acid reabsorption and increasing urinary uric acid excretion. This lowers serum uric acid by approximately 20–25% in clinical studies — a clinically meaningful effect making losartan the preferred ARB in hypertensive patients with gout or hyperuricemia. This property is not shared by other ARBs (valsartan, irbesartan, olmesartan), making it drug-specific rather than class-wide.
Option A: Option A is incorrect — amlodipine does not inhibit xanthine oxidase; xanthine oxidase inhibition is the mechanism of allopurinol and febuxostat.
Option B: Option B is incorrect and clinically important: thiazide diuretics increase serum uric acid by competing with urate at the proximal tubular organic anion secretion transporter, reducing urate secretion and causing hyperuricemia — the opposite of a uricosuric effect; thiazides can precipitate gout attacks.
Option D: Option D is incorrect — ACE inhibitors do not meaningfully reduce xanthine oxidase activity through the mechanism described.
Option E: Option E is incorrect — beta-blockers are associated with modest increases in serum uric acid, not the uricosuric effect described.
8. A 68-year-old woman with hypertension is started on hydrochlorothiazide 25 mg daily. Six weeks later her sodium is 126 mEq/L and she is confused and lethargic. Which patient characteristics identified at her initial visit would have most specifically predicted her high risk for this complication?
A) Female sex, older age, low body weight, and baseline low-normal serum sodium — this profile identifies the patient at highest risk for thiazide-induced hyponatremia, in which non-osmotic ADH release combined with impaired urinary dilution from NCC blockade causes free water retention that dilutes serum sodium
B) Her age of 68 alone, because all elderly patients develop thiazide-induced hyponatremia within 6 weeks of initiation and the complication is universal in this age group
C) Baseline serum potassium level, because thiazide-induced hyponatremia occurs exclusively through kaliuresis-driven cellular sodium shifts and is entirely predicted by baseline potassium
D) Use of any concurrent antihypertensive medication, because pharmacokinetic drug interactions between thiazides and other antihypertensives universally impair renal sodium handling
E) High dietary sodium intake, because thiazide-induced hyponatremia occurs only in patients with high dietary sodium intake who develop a paradoxical natriuretic response exceeding sodium consumption
ANSWER: A
Rationale:
This question asked you to identify the patient characteristics predicting high risk for thiazide-induced hyponatremia. Option A is correct: thiazide-induced hyponatremia is a well-characterized, potentially life-threatening complication with a consistent high-risk patient profile. Thiazides block the NCC cotransporter in the distal convoluted tubule, preventing urinary dilution in this segment. When combined with non-osmotic ADH release — stimulated by volume contraction — the kidney reabsorbs free water in the collecting duct while being unable to excrete dilute urine. The highest-risk patients are female (estrogen may potentiate ADH release and impair renal water excretion), older (reduced renal concentrating and diluting capacity), low body weight (low total body water means the same free water gain produces a larger fall in sodium concentration), and have baseline low-normal sodium. Recognizing this profile before prescribing should prompt either selection of an alternative antihypertensive, closer monitoring, or a lower thiazide dose.
Option B: Option B is incorrect — thiazide-induced hyponatremia is not universal in the elderly; it occurs in a subset with identifiable risk factors.
Option C: Option C is incorrect — the primary mechanism is water retention from ADH, not solely kaliuresis-driven sodium shifts.
Option D: Option D is incorrect — concurrent antihypertensive use does not universally predict thiazide hyponatremia through pharmacokinetic interaction.
Option E: Option E is incorrect — thiazide hyponatremia is not limited to high dietary sodium intake and does not occur through the paradoxical natriuresis mechanism described.
9. A 73-year-old man with hypertension and moderate BPH-related lower urinary tract symptoms presents for antihypertensive selection. BP is 152/94 mmHg on no current antihypertensives. Which antihypertensive agent achieves both BP reduction and improvement in BPH symptoms through a shared mechanism, and what is the most important tolerability consideration?
A) Lisinopril, because ACE inhibitor-mediated reduction in Ang II decreases smooth muscle tone in the prostate through AT1 receptor-dependent pathways, improving urinary flow
B) Metoprolol succinate, because beta-1 selective blockade reduces sympathetically mediated prostate smooth muscle contraction, directly improving lower urinary tract symptoms
C) Doxazosin or terazosin, because alpha-1 adrenergic receptor blockade relaxes smooth muscle in both resistance arterioles (lowering BP) and the prostate and bladder neck (reducing outlet obstruction and improving urinary flow) through the same mechanism; the most important tolerability concern is first-dose orthostatic hypotension, for which bedtime dosing is recommended
D) Chlorthalidone, because thiazide-mediated reduction in intravascular volume reduces prostatic edema, indirectly relieving the mechanical component of urinary obstruction
E) Amlodipine, because L-type calcium channel blockade in prostatic smooth muscle reduces contractile tone and directly improves urinary flow independent of vascular effects
ANSWER: C
Rationale:
This question asked you to identify the antihypertensive agent providing pharmacological benefit for both hypertension and BPH through a shared mechanism. Option C is correct: alpha-1 adrenergic receptor blockers — doxazosin, terazosin, prazosin — relax vascular smooth muscle in resistance arterioles by blocking postsynaptic alpha-1 receptors, lowering systemic vascular resistance and BP. The same alpha-1 receptors are expressed in smooth muscle of the prostate, bladder neck, and urethra; alpha-1 blockade reduces tone in these tissues, decreasing urethral resistance and improving urinary flow. This dual pharmacological benefit makes alpha-1 blockers rational when both hypertension and BPH coexist. The most important tolerability concern is first-dose orthostatic hypotension — patients should be counseled to take the first dose at bedtime — and alpha-1 blockers are not recommended as first-line antihypertensives in patients with established cardiovascular disease due to outcomes data.
Option A: Option A is incorrect — ACE inhibitors do not relax prostatic smooth muscle through AT1 receptor pathways; prostate smooth muscle tone is predominantly adrenergically mediated.
Option B: Option B is incorrect — beta-1 selective blockade does not reduce prostatic smooth muscle tone; prostatic smooth muscle is predominantly alpha-1 adrenoceptor-mediated.
Option D: Option D is incorrect — chlorthalidone does not reduce prostatic edema in the manner described; this is pharmacologically fabricated.
Option E: Option E is incorrect — amlodipine does not have a clinically established benefit for BPH symptoms at therapeutic doses.
10. A 44-year-old woman develops angioedema — facial and lip swelling without urticaria — 3 weeks after starting ramipril. The ramipril is stopped and the angioedema resolves over 48 hours. Six months later her BP is again uncontrolled. Her physician wishes to start sacubitril-valsartan, given its cardiovascular outcome benefits. Which of the following most accurately describes the risk of this decision?
A) Sacubitril-valsartan is absolutely safe after ACE inhibitor angioedema because the valsartan component is an ARB that does not affect ACE activity, and the sacubitril component blocks neprilysin rather than ACE
B) Sacubitril-valsartan carries a small but real risk of angioedema comparable to that of an ARB alone in patients with prior ACE inhibitor angioedema, because neprilysin inhibition has no effect on bradykinin metabolism
C) Sacubitril-valsartan is contraindicated after ACE inhibitor-induced angioedema; sacubitril inhibits neprilysin, one of the enzymes responsible for bradykinin degradation, meaning this combination substantially elevates bradykinin levels in a patient who has already demonstrated bradykinin-mediated vascular permeability — substantially increasing the risk of recurrent angioedema
D) Sacubitril-valsartan is preferred over a plain ARB after ACE inhibitor angioedema because neprilysin inhibition produces anti-inflammatory effects that reduce bradykinin receptor sensitivity and lower the threshold for angioedema recurrence
E) ARBs are absolutely contraindicated after ACE inhibitor-induced angioedema because both drug classes inhibit ACE and produce identical bradykinin accumulation; sacubitril-valsartan is therefore also contraindicated for the same reason
ANSWER: C
Rationale:
This question asked you to identify the risk of sacubitril-valsartan specifically after ACE inhibitor-induced angioedema. Option C is correct: ACE inhibitor angioedema is bradykinin-mediated — ACE inhibition prevents bradykinin degradation, causing local bradykinin accumulation in submucosal tissues and producing the characteristic non-urticarial angioedema. Sacubitril-valsartan (Entresto) combines valsartan (an ARB) with sacubitril (a neprilysin inhibitor). Neprilysin is one of the enzymes — along with ACE, aminopeptidase P, and carboxypeptidase N — that normally degrades bradykinin. When neprilysin is inhibited, bradykinin degradation is further impaired. In a patient who has already demonstrated pathological bradykinin-mediated angioedema with ACE inhibition, adding neprilysin inhibition creates a substantially elevated risk of recurrent angioedema — because now a second degradation pathway is blocked. Sacubitril-valsartan is therefore specifically contraindicated after ACE inhibitor angioedema. A plain ARB (which does not inhibit ACE or neprilysin and does not affect bradykinin degradation) carries a much lower risk and is a reasonable alternative.
Option A: Option A is incorrect — the sacubitril component does affect bradykinin metabolism by blocking neprilysin.
Option B: Option B is incorrect — neprilysin inhibition does directly affect bradykinin metabolism; the risk is higher than that of an ARB alone in this context.
Option D: Option D is incorrect and dangerous — neprilysin inhibition does not produce anti-inflammatory effects that reduce bradykinin receptor sensitivity; it worsens bradykinin accumulation.
Option E: Option E is incorrect — ARBs do not inhibit ACE and do not directly increase bradykinin levels; they carry a lower but non-zero risk in this setting, not the same risk as ACE inhibitors.
11. A 59-year-old insulin-treated diabetic man with hypertension is started on metoprolol succinate. At follow-up he reports that his hypoglycemia awareness has diminished — he no longer experiences the palpitations and tremor that previously warned him of low blood glucose. Which of the following best explains this adverse effect and identifies a safer antihypertensive alternative?
A) Beta-blockers mask the adrenergic symptoms of hypoglycemia — palpitations, tremor, and anxiety — by blocking the sympathetic response to falling blood glucose; sweating (a cholinergic response) is preserved; a dihydropyridine CCB such as amlodipine does not affect adrenergic hypoglycemia awareness and is a safer antihypertensive in insulin-treated diabetic patients who rely on these symptoms
B) Metoprolol causes hypoglycemia directly by blocking beta-2 receptors on pancreatic alpha cells, suppressing glucagon release and preventing the glucagon-mediated counterregulatory response to low blood glucose; a CCB is preferred because it has no effect on glucagon secretion
C) Metoprolol-induced impaired hypoglycemia awareness occurs solely through beta-1 blockade that prevents tachycardia — as tachycardia is the only adrenergic warning of hypoglycemia, beta-1 selective agents cause the same degree of masking as non-selective beta-blockers
E) Metoprolol reduces hypoglycemia awareness by inhibiting hepatic glucokinase through beta-1 receptor-mediated pathways, preventing hepatic glucose sensing and eliminating the reflex sympathoadrenal activation that generates hypoglycemia warning symptoms
ANSWER: A
Rationale:
This question asked you to identify the mechanism of beta-blocker-induced impaired hypoglycemia awareness and identify a safer antihypertensive alternative. Option A is correct: when blood glucose falls, the sympathoadrenal system generates adrenergic warning symptoms — palpitations, tremor, anxiety — primarily through beta-2 adrenergic receptor stimulation. Beta-blockers, even beta-1 selective agents like metoprolol, have residual beta-2 activity especially at higher doses and blunt these adrenergic warning signs, leaving the patient unaware of developing hypoglycemia until neuroglycopenic symptoms (confusion, loss of consciousness) appear. Sweating is a cholinergic response and is preserved during beta-blocker use — patients should be counseled to rely on sweating as a hypoglycemia warning. Additionally, beta-2 blockade impairs hepatic glycogenolysis, potentially prolonging hypoglycemia. Dihydropyridine CCBs do not affect adrenergic signaling or hypoglycemia awareness and are safe in insulin-treated diabetic patients.
Option B: Option B incorrectly frames glucagon suppression as the primary mechanism of impaired awareness — the primary clinical issue is masking of adrenergic warning symptoms, not direct hypoglycemia induction.
Option C: Option C is incorrect — hypoglycemia awareness involves the full adrenergic symptom complex beyond tachycardia alone, and beta-2-mediated symptoms are at least as important as beta-1-mediated tachycardia.
Option D: Option D is incorrect — beta-blockers do not cause diabetic autonomic neuropathy; this is a disease-related complication, not drug-induced.
Option E: Option E is incorrect — beta-blockers do not inhibit hepatic glucokinase through beta-1 receptor-mediated pathways; this mechanism is fabricated.
12. A 66-year-old man with hypertension, atrial fibrillation on warfarin, and no structural heart disease has BP of 156/94 mmHg on amlodipine 5 mg daily. His cardiologist wishes to add a rate-controlling agent that also intensifies BP control. Which of the following correctly identifies the agent that achieves both goals and the most clinically important drug interaction with warfarin?
A) Metoprolol succinate controls ventricular rate and lowers BP through beta-1 blockade; the most important interaction is that beta-blockers inhibit CYP2C9, increasing warfarin levels and requiring INR monitoring
B) Diltiazem or verapamil slow AV nodal conduction and lower BP through non-dihydropyridine CCB activity; the most important interaction is moderate CYP3A4 and P-glycoprotein inhibition that can modestly increase warfarin levels, requiring INR monitoring
C) Digoxin controls ventricular rate through vagal enhancement and lowers BP through improved cardiac output; the most important interaction is digoxin-warfarin competition for renal tubular secretion
D) Amiodarone controls ventricular rate through multiple ion channel effects and lowers BP through alpha-adrenergic blockade; the most important and clinically severe interaction is potent CYP2C9 inhibition that markedly increases S-warfarin levels by 30–50% or more — an effect that persists for weeks to months after amiodarone discontinuation due to its extremely long half-life (40–55 days), mandating significant warfarin dose reduction and frequent INR monitoring
E) Flecainide controls ventricular rate through sodium channel blockade and lowers BP through negative inotropy; the most important interaction is plasma protein binding competition with warfarin
ANSWER: D
Rationale:
This question asked you to identify the agent achieving both rate control in AF and BP reduction, and the most clinically important drug interaction with warfarin. Option D is correct on both accounts: amiodarone controls ventricular rate in AF through its effects on the AV node (class III potassium channel blockade, beta-blocking activity, calcium channel blocking activity, and sodium channel effects), and it lowers BP through alpha-1 adrenergic blockade. The drug interaction with warfarin is among the most clinically significant in all of cardiovascular pharmacology: amiodarone and its active metabolite desethylamiodarone are potent inhibitors of CYP2C9 — the primary enzyme metabolizing the pharmacologically active S-warfarin enantiomer. This interaction increases warfarin's anticoagulant effect by 30–50% or more, and because amiodarone has an extremely long half-life (40–55 days), the interaction persists for weeks to months after amiodarone is discontinued. Frequent INR monitoring and substantial warfarin dose reduction are mandatory when these agents are co-administered. Option B contains a partial truth — diltiazem and verapamil do modestly inhibit CYP3A4 and P-glycoprotein — but the magnitude and clinical severity is considerably less than the amiodarone-warfarin interaction.
Option A: Option A is incorrect — beta-blockers do not significantly inhibit CYP2C9 and do not meaningfully alter warfarin levels.
Option C: Option C is incorrect — digoxin controls ventricular rate but does not lower BP through positive inotropy in the manner described, and the digoxin-warfarin interaction mechanism is not renal tubular competition.
Option E: Option E is incorrect — flecainide is a rhythm control agent, not a rate control agent, and the interaction mechanism described is fabricated.
13. A 49-year-old woman with treatment-resistant hypertension (BP 162/104 mmHg on maximum doses of lisinopril, amlodipine, and chlorthalidone) has normal renal function, normal aldosterone-to-renin ratio, and no identified secondary causes. Adherence has been confirmed by urine drug screening. Which of the following represents the most evidence-based next pharmacological step?
A) Add hydralazine as the fourth agent because direct arterial vasodilation through smooth muscle cGMP-independent mechanisms overcomes resistance to neurohormonal drug classes
B) Add a second RAAS inhibitor — an ARB added to the ACE inhibitor — to achieve dual RAAS blockade, which produces additional BP reduction in resistant hypertension beyond single RAAS blockade
C) Refer immediately for renal denervation, as catheter-based renal sympathetic denervation is the guideline-mandated next step after confirmed three-drug failure with documented adherence
D) Add low-dose spironolactone (25–50 mg daily) — the PATHWAY-2 (a randomized crossover trial demonstrating spironolactone superiority as fourth-line agent in resistant hypertension) trial demonstrated that mineralocorticoid receptor antagonism produces substantially greater additional BP reduction than bisoprolol, doxazosin, or placebo as a fourth agent in true resistant hypertension, because aldosterone-mediated volume expansion is the dominant mechanism even when the formal aldosterone-to-renin ratio (ARR) is not diagnostically elevated
E) Add clonidine because central alpha-2 agonism suppresses sympathetic outflow through a mechanism entirely distinct from peripheral vasodilators and RAAS inhibitors, and clonidine is the current guideline-standard fourth-line agent
ANSWER: D
Rationale:
This question asked you to identify the most evidence-based fourth-line pharmacological addition for true resistant hypertension. Option D is correct: the PATHWAY-2 trial — the landmark randomized crossover study specifically designed to identify the best add-on therapy in resistant hypertension — demonstrated that spironolactone at 25–50 mg daily produced substantially greater additional BP reduction than bisoprolol, doxazosin, or placebo as a fourth agent added to triple therapy including a diuretic. The mechanistic basis is that true resistant hypertension is disproportionately driven by aldosterone-mediated volume expansion even when the formal ARR does not reach diagnostic thresholds for primary aldosteronism. Mineralocorticoid receptor antagonism at low doses addresses this pathophysiology directly. Spironolactone is now the recommended fourth-line agent in international guidelines for resistant hypertension.
Option A: Option A is incorrect — hydralazine is not the evidence-based fourth-line agent for resistant hypertension and is associated with reflex tachycardia and lupus-like syndrome with prolonged use.
Option B: Option B is incorrect and potentially harmful — dual RAAS blockade combining ACE inhibitors and ARBs was evaluated in ONTARGET (a dual RAAS blockade trial — ramipril plus telmisartan — that showed increased adverse effects without cardiovascular benefit) and shown to produce more adverse effects (hyperkalemia, AKI) without additional cardiovascular benefit; dual RAAS blockade is not recommended.
Option C: Option C is incorrect — renal denervation is investigational with emerging evidence but is not the guideline-mandated next step; pharmacological options remain first.
Option E: Option E is incorrect — clonidine is sometimes used as a fourth agent in resistant hypertension but lacks the robust randomized controlled trial (RCT) evidence supporting spironolactone and carries risks of rebound hypertension on abrupt discontinuation.
14. A 77-year-old man with ISH (BP 176/66 mmHg, pulse pressure 110 mmHg), a prior fall with hip fracture 8 months ago, moderate cognitive impairment, and eGFR of 42 mL/min/1.73m² is evaluated for antihypertensive intensification. His geriatrician is concerned about the risks of aggressive BP lowering. Which of the following most accurately frames the evidence-based approach in this patient?
A) BP should be lowered aggressively to below 120/80 mmHg in all patients regardless of age, frailty, or cognitive status, as SPRINT (a trial of intensive vs standard BP targets — SBP goal 120 vs 140 mmHg — in high-risk non-diabetic adults) demonstrated uniform cardiovascular benefit across all subgroups
B) Antihypertensive therapy should be discontinued entirely in patients over 75 with cognitive impairment and prior falls, as any BP lowering in this demographic carries net harm without cardiovascular benefit
C) Calcium channel blockers are contraindicated in frail elderly patients with ISH because their afferent vasodilatory mechanism lowers diastolic pressure preferentially, worsening the already low diastolic blood pressure (DBP) of 66 mmHg and precipitating coronary hypoperfusion
D) A conservative approach targeting systolic blood pressure (SBP) 140–150 mmHg is appropriate in this frail elderly patient — aggressive BP lowering in older frail adults with cognitive impairment, orthostatic hypotension risk, and prior falls carries risks of falls, syncope, AKI, and cognitive worsening that may outweigh the cardiovascular benefit achievable at lower targets; agent selection should favor agents with low orthostatic hypotension risk and avoid excessive diastolic lowering given the already low DBP of 66 mmHg
E) Beta-blockers are the preferred antihypertensive in all elderly patients with ISH because their negative chronotropic effect prevents reflex tachycardia from low diastolic pressure, protecting against coronary hypoperfusion
ANSWER: D
Rationale:
This question asked you to apply an individualized, evidence-based approach to hypertension management in a frail elderly patient with multiple competing risks. Option D is correct: in frail elderly patients — particularly those with prior falls, cognitive impairment, and very low diastolic pressure — the evidence for aggressive BP lowering is less certain than in younger or non-frail populations. The SPRINT trial excluded patients with dementia, required ambulatory function, and used automated office BP measurements that are typically 5–10 mmHg lower than standard office measurements, making its results less directly applicable to frail older adults with cognitive impairment. The J-curve hypothesis — that excessive lowering of diastolic BP may impair coronary perfusion — is particularly relevant when DBP is already 66 mmHg. The prior hip fracture and fall history make orthostatic hypotension from overly aggressive BP reduction a major safety concern. A conservative SBP target of 140–150 mmHg with careful attention to orthostatic symptoms and agent selection favoring low orthostatic hypotension risk is the appropriate individualized approach.
Option A: Option A incorrectly applies SPRINT uniformly to all elderly patients — SPRINT excluded frail patients with dementia, and its results are not directly applicable here.
Option B: Option B is incorrect — the evidence supports treating hypertension in patients over 75 with individualized targets; complete discontinuation is not appropriate.
Option C: Option C is incorrect — calcium channel blockers do not preferentially lower diastolic pressure in ISH; they are actually reasonable agents in this setting when used carefully.
Option E: Option E is incorrect — beta-blockers are not preferred for ISH in the elderly; they primarily reduce cardiac output with less effect on the arterial stiffness driving ISH, and their negative chronotropic effects can be problematic in frail elderly patients.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.